Alcobra Pharmaceuticals
Treatment of Cognitive Disorders
Company Name | Updating Date | Neurotech Category | Market Category | Target Market | Technologies | Company Founded Year | Company Number of Employees |
|---|---|---|---|---|---|---|---|
Alcobra Pharmaceuticals | Biotechnology & Biopharmaceutical | 01/01/2008 | "11-50" |
Alcobra Pharmaceuticals is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug, Metadoxine Extended Release (MDX), designed to treat cognitive disorders including attention-deficit/hyperactivity disorder (ADHD) and Fragile X syndrome.
MDX is not a stimulant and works through a different mechanism of action than other ADHD treatments. Alcobra has completed multiple phase 2 studies and a phase 3 study of MDX in adults with ADHD. The company is conducting separate phase 2b trials of MDX in patients with pediatric ADHD and Fragile X syndrome.
In 2017, six months after Alcobra’s clinical trial of its main product for treating attention disorders failed, the company announced its intention to merge with Arcturus Therapeutics Inc of San Diego.